Clinical trial NCT06808321: Benidipine in Hypertensive And/or Chronic Coronary Syndrome Patients
Official title: Evaluation of Clinical Outcomes of Benidipine in Hypertensive And/or Chronic Coronary Syndrome Patients in the Turkish Population
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Chronic Coronary Syndrome
Hypertension
Angina Pectoris
Keywords: Coronary artery disease
Hypertension
Angina pectoris
Lead sponsor: The Society of Prevention and Awareness of Cardiovascular Diseases
Sponsor class: OTHER
First posted: 2025-02-05
Enrollment: 800
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients presenting to cardiology outpatient clinics in Turkey with hypertension and/or angina pectoris (chronic coronary syndrome)

Brief summary: Evaluation of the clinical outcomes of Benidipine initiated by physician's preference in patients with hypertension and/or angina pectoris (chronic coronary syndrome) presenting to cardiology outpatient clinics in Turkey.

Detailed description: * Benidipine is a dihydropyridine calcium channel blocker used in the treatment of hypertension and angina pectoris. There are currently no large-scale observational studies in these patient groups in Turkey.
* There is no record of benidipine in clinicaltrials.gov, which is an important database especially for the registration of drug and interventional studies.
* Therefore, it will be extremely important to include this study in clinicaltrials.gov and to evaluate the clinical efficacy of Bendipine in patients with hypertensive and/or angina pectoris in 7 geographical regions of Turkey.

Eligibility criteria: Inclusion Criteria:

* Patients with hypertension and/or angina pectoris on the background of chronic coronary syndrome who have been receiving Benidipine treatment for at least 1 month and will continue to receive Benidipine treatment
* Male or female outpatients, 18-80 years of age
* Patients with mild to moderate essential hypertension who have been receiving or will continue Benidipine treatment for at least 1 month
* Outpatients with clinically stable angina pectoris and patients who have been receiving or will continue Benidipine treatment for at least 1 month
* Those who signed the written informed consent form

Exclusion Criteria:

* Patients with secondary hypertension
* Emergency hypertensive patients
* Having to take other medications during the study that may affect blood pressure
* Allergic to DHP calcium antagonists
* Evidence of decompensated congestive heart failure, unstable angina or severe arrhythmia
* Severe renal or hepatic dysfunction
* Pregnant or lactating women
* Participation in other clinical trials within 3 months prior to this study
* Patients who did not sign the consent form of the study

Primary outcomes:
measure: The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85
timeFrame: 3 months
measure: Change in angina symptom severity as measured by the Seattle Angina Questionnaire score from baseline to the end of study
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: